Compare DexCom, Inc. (DXCM) vs Ulta Beauty Inc (ULTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Ulta Beauty Inc — how do they compare? DexCom, Inc. trades at $78.01 (market cap $28.06B), while Ulta Beauty Inc trades at $477.32 (market cap $20.04B). The key difference: DexCom, Inc. is the larger of the two by market cap, and DexCom, Inc. is trading nearer its 52-week high, Ulta Beauty Inc nearer its low. Which is the better fit depends on your goals.
| DXCM | ULTA | |
|---|---|---|
Market Cap | $28.06B | $20.04B |
Sector | Health | Consumer Cyclical |
52-Week High | $89.53 | $706.82 |
52-Week Low | $54.84 | $450.75 |
Enterprise Value | $27.03B | $22.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
ULTA Beauty trades at $469.12, down 0.89% on the day, with a neutral technical signal and mixed earnings history. The stock shows strong profitability with a 39.33% gross margin and 47.45% ROE, though revenue growth has moderated. Recent news highlights international expansion and a new CTO appointment, while analyst consensus remains bullish with a $623.73 price target.
Outlook: ULTA presents a value opportunity with solid fundamentals and market share gains, but faces risks from consumer demand volatility and competitive pressures. Wall Street's strong buy ratings suggest upside potential, though investors should monitor margin trends and execution of growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Ulta Beauty Inc
With more than 1,300 stores and a partnership with Target, Ulta Beauty is the largest specialized beauty retailer in the U.S. The firm offers makeup (43% of 2021 sales), fragrances, skin care, and hair care products (20% of 2021 sales), and bath and body items. Ulta offers private-label products and merchandise from more than 500 vendors. It also offers salon services, including hair, makeup, skin, and brow services, in all stores. Most Ulta stores are approximately 10,000 square feet and are in suburban strip centers. Ulta was founded in 1990 and is based in Bolingbrook, Illinois.
Read more on ULTA →
